Clinical trials: RDS
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.
Acute Respiratory Distress Syndrome
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis
This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients.
- Trial name
- NCT07439848
- Testing
- Control (NaCl 0.9%), UC-MSC, UC-MSC and Secretome
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06703073
- Testing
- Cohort A: vilobelimab, Cohort B: paridiprubart, Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- PPD Development, LP
RDS of Prematurity, Preterm Birth
Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates
Pivotal study to assess safety and performance of Neola®, a novel lung monitoring device for neonates
- Conditions
- RDS of Prematurity, Preterm Birth, Lung Diseases
- Trial name
- NCT07060911
- Testing
- Lung monitoring with the Neola device
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Neola Medical Inc
Acute Respiratory Distress Syndrome, Respiratory Failure
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
- Conditions
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases
- Trial name
- SUMMIT (NCT06308926)
- Testing
- MRG-001 (Low-dose), MRG-001 (High-dose)
- Volunteers
- 60 people
- Sponsor
- MedRegen LLC
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701669
- Testing
- Cohort B: paridiprubart
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
2019 Novel Coronavirus Infection, COVID-19 Virus Infection
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection
- Trial name
- NCT04778059
- Testing
- USB002
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Biotest, Inc.
Respiratory Distress Syndrome
Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients
Study to test the hypothesis that aerosolized Infasurf can decrease the need for intubation and instillation of liquid surfactant to the airway.
- Trial name
- NCT03058666
- Testing
- Aerosolized Calfactant, Solarys
- Where
- 22 sites in United States
- Volunteers
- 477 people
- Sponsor
- ONY
Complex Regional Pain Syndrome I (CRPS I)
CRPS-RISE Outcomes Registry
The goal of this observational study is to learn about how well neridronate keeps working in the months after treatment. For 12 or up to 24 months while the registry is open participants will answer online survey questions about…
- Trial name
- NCT07811362
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Ambros Therapeutics, Inc.
Neonatal Respiratory Distress Syndrome
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
The present study will mainly aim at investigating the safety, tolerability and efficacy of different escalating single doses administration of nebulised Curosurf®, in preterm neonates with RDS (Respiratory Distress Syndrome)…
- Trial name
- NCT03235986
- Testing
- nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I), nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II), nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
Acute Respiratory Distress Syndrome
Safety and Efficacy Study of Acthar in Subjects With ARDS
This study is being performed to evaluate the potential efficacy and safety of Acthar as a treatment for moderate-severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT02113735
- Testing
- H.P. Acthar® Gel (repository corticotropin injection)
- Sponsor
- Mallinckrodt
Respiratory Distress Syndrome (Neonatal), Intubation Complication
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated…
- Conditions
- Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
- Trial name
- Aero-05 (NCT05960929)
- Testing
- Infasurf Aero™
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- ONY
Respiratory Distress Syndrome, Pre-term Infants
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham).
- Trial name
- NCT06776783
- Testing
- APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 520 people
- Sponsor
- Aerogen Pharma Limited
Acute Respiratory Distress Syndrome, Ards
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to…
- Trial name
- NCT04909879
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
Respiratory Disorders
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing. The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the…
- Trial name
- NCT01476046
- Testing
- GSK1995057 single dose
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Respiratory Distress Syndrome, Covid19
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
- Trial name
- NCT04524962
- Testing
- Descartes 30
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cartesian Therapeutics
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Acute Respiratory Distress Syndrome
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
Evaluate the safety, tolerability, efficacy and pharmacodynamics\&pharmacokinetic properties of CT303 in patients with ARDS.
- Trial name
- NCT05238532
- Testing
- CT303
- Where
- 3 sites in South Korea
- Sponsor
- GC Cell Corporation
COVID-19 Pneumonia, COVID-19
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
COVID-19 has multiple facets including cytokine storm, thromboembolism and gelatinous secretions. It is known that oxygen exchange is the main problem in patients with COVID-19 and hypoxia is one of the most serious, in which…
- Conditions
- COVID-19 Pneumonia, COVID-19, Ventilator Associated Pneumonia, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05258682
- Testing
- Bromelains, Acetylcysteine
- Volunteers
- 30 people
- Sponsor
- Mucpharm Pty Ltd